€43.77 Qiagen (QIA.DE XETRA) intraday 03 Feb 2026 ahead of earnings: what to watch
QIA.DE stock trades at €43.77 intraday on XETRA as investors position ahead of Qiagen N.V.’s earnings due 04 Feb 2026. We focus on revenue drivers, margins and cash flow that can move shares after the report. The trading range today is €43.62–€44.06 on volume 54,820 shares, below the 50-day average of €42.10. This earnings spotlight frames likely surprises and market reactions for Germany-listed Qiagen (Qiagen N.V., QIA.DE)
Earnings preview: QIA.DE stock and the Feb 4 report
Qiagen reports earnings on 04 Feb 2026, and consensus attention will center on margin recovery and product mix in Diagnostics and Life Sciences. Analysts will watch EPS versus the trailing EPS of €1.63 and revenue trends against recent weakness in gross profit growth. One near-term risk is softer demand in routine testing, which could pressure operating margins and the PE of 27.03.
Key financials and valuation for QIA.DE stock
Qiagen shows a trailing PE of 27.03, EPS €1.63, and a dividend per share of €2.69, implying a yield near 5.17%; price-to-book is 3.09. The balance sheet is solid with a current ratio of 2.60 and net debt to EBITDA around 0.94, supporting the yield and dividend sustainability. Investors should weigh the 12.31 enterprise value multiple and free cash flow yield 4.44% when assessing value.
Meyka AI grade and forecast for QIA.DE stock
Meyka AI rates QIA.DE with a score out of 100: 71.26 | Grade B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of €40.22, implying -8.07% versus the current €43.77, and monthly forecast €38.68 implying -11.61%; forecasts are model-based projections and not guarantees.
Technical and trading snapshot for QIA.DE stock
Intraday price action shows resistance near the year high €47.60 and support near €36.04; today’s volume 54,820 is below the 3-month average 593,242, limiting directional conviction. Momentum indicators are mixed: RSI 65.64, MACD histogram positive, and CCI overbought, which suggests limited upside without a fundamental catalyst. Traders should watch the day range €43.62–€44.06 and short-term moving averages at €42.10 (50-day) and €42.19 (200-day).
Risks and catalysts shaping QIA.DE stock
Catalysts include stronger-than-expected molecular testing sales, updates on strategic partnerships, and margin recovery from cost saves; risks include softer routine testing demand and currency headwinds. Regulatory approvals or major OEM orders could lift forward guidance, while disappointing revenue mix or lower-than-expected guidance would likely trigger a re-rating. Sector context: Healthcare peers trade at average PE 33.39, leaving relative valuation room for Qiagen if growth improves.
Analyst scenarios and price targets for QIA.DE stock
Base-case price target: €44.00, bull-case: €50.00, conservative: €36.00, reflecting different margin and growth outcomes after earnings. The base case values Qiagen on near-term EPS expansion and stable cash flow, yielding limited upside from current price. The conservative scenario assumes margin pressure and revisions, which would create downside near the year low.
Final Thoughts
QIA.DE stock trades at €43.77 intraday on XETRA as market participants await the 04 Feb 2026 earnings print. Our review highlights a mixed fundamental picture: solid cash generation and a generous dividend against recent margin compression and slowing EPS growth. Meyka AI’s model projects a yearly price of €40.22, implying -8.07% from today, while shorter-term monthly projection is €38.68. Investors should weigh the PE 27.03, dividend yield 5.17%, and balance-sheet strength against downside risk from weak testing demand. For traders, watch guidance, margin commentary and volume; for longer-term investors, focus on cash flow trends and R&D leverage. Meyka AI, an AI-powered market analysis platform, provides these model-based projections for context only — forecasts are not guarantees and we are not financial advisors.
FAQs
When does Qiagen (QIA.DE) report earnings?
Qiagen’s next earnings announcement is scheduled for 04 Feb 2026; markets will watch EPS, revenue mix and margin guidance closely. The report will likely move QIA.DE stock intraday depending on surprises.
What is Meyka AI’s view on QIA.DE stock?
Meyka AI rates QIA.DE 71.26 (B+), Suggestion: BUY and projects a yearly price of €40.22, noting balanced fundamentals and dividend support. Grades and forecasts are model outputs, not investment advice.
Which metrics should investors watch in the earnings report?
Focus on organic revenue growth, gross margin, EPS versus €1.63 trailing, free cash flow trends and any guidance change, as these drive valuation and the current PE 27.03.
How does QIA.DE stock compare with the healthcare sector?
Qiagen trades below some peer PEs but above sector medians on price-to-book; sector average PE is 33.39, so margin recovery could narrow valuation gaps and support upside.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.